CryoPort (NASDAQ:CYRX) CEO Sells $23,672.92 in Stock

CryoPort, Inc. (NASDAQ:CYRX) CEO Jerrell Shelton sold 2,894 shares of the business’s stock in a transaction dated Monday, March 23rd. The stock was sold at an average price of $8.18, for a total transaction of $23,672.92. Following the completion of the sale, the chief executive officer owned 1,051,607 shares in the company, valued at approximately $8,602,145.26. This trade represents a 0.27% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Jerrell Shelton also recently made the following trade(s):

• On Monday, March 16th, Jerrell Shelton sold 7,918 shares of CryoPort stock. The shares were sold at an average price of $8.00, for a total transaction of $63,344.00.

CryoPort Trading Down 4.8%

NASDAQ:CYRX opened at $7.82 on Friday. The company has a 50-day moving average of $8.77 and a 200-day moving average of $9.30. The firm has a market cap of $389.91 million, a price-to-earnings ratio of 5.92 and a beta of 1.69. CryoPort, Inc. has a twelve month low of $4.63 and a twelve month high of $11.45.

CryoPort (NASDAQ:CYRX) last released its earnings results on Tuesday, March 3rd. The company reported ($0.21) EPS for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.02). CryoPort had a negative return on equity of 8.22% and a net margin of 42.35%.The business had revenue of $45.45 million during the quarter, compared to the consensus estimate of $42.92 million. On average, research analysts forecast that CryoPort, Inc. will post -0.99 earnings per share for the current year.

Analyst Ratings Changes

A number of brokerages have recently commented on CYRX. Needham & Company LLC increased their price objective on CryoPort from $12.00 to $13.00 and gave the company a “buy” rating in a research report on Wednesday, March 4th. Wall Street Zen cut CryoPort from a “hold” rating to a “sell” rating in a report on Saturday, March 7th. Finally, Weiss Ratings reaffirmed a “sell (d+)” rating on shares of CryoPort in a research report on Monday, December 29th. Eight equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $12.94.

Institutional Investors Weigh In On CryoPort

A number of large investors have recently made changes to their positions in CYRX. LPL Financial LLC boosted its stake in CryoPort by 6.6% in the 4th quarter. LPL Financial LLC now owns 23,306 shares of the company’s stock worth $224,000 after purchasing an additional 1,433 shares during the period. The Manufacturers Life Insurance Company raised its stake in CryoPort by 9.4% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 18,178 shares of the company’s stock valued at $136,000 after purchasing an additional 1,557 shares during the period. State of Wyoming raised its stake in CryoPort by 30.2% during the 2nd quarter. State of Wyoming now owns 14,218 shares of the company’s stock valued at $106,000 after purchasing an additional 3,301 shares during the period. Intech Investment Management LLC lifted its holdings in shares of CryoPort by 14.6% in the second quarter. Intech Investment Management LLC now owns 25,951 shares of the company’s stock valued at $194,000 after purchasing an additional 3,305 shares in the last quarter. Finally, Basepoint Wealth LLC purchased a new stake in shares of CryoPort in the fourth quarter valued at $34,000. Institutional investors and hedge funds own 92.90% of the company’s stock.

CryoPort Company Profile

CryoPort, Inc (NASDAQ: CYRX) is a global provider of temperature-controlled logistics solutions for the life sciences industry. The company specializes in cryogenic shipping for critical biological materials, supporting the development, clinical testing and commercialization of cell and gene therapies, biologics, vaccines and reproductive medicine. By offering end-to-end supply chain management, CryoPort helps ensure the integrity and viability of temperature-sensitive products from point of origin to destination.

CryoPort’s product portfolio includes proprietary cryogenic dry shippers, advanced active and passive thermal packaging, and real-time data monitoring platforms.